Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Baylor1965on Apr 07, 2017 10:38am
236 Views
Post# 26091264

RE:Trillium Therapeutics Investment Highlights as of Apr 5/17

RE:Trillium Therapeutics Investment Highlights as of Apr 5/17 It's amazing how this is under the mainstream's radar! Management needs to raise funds through another round and I'm sure financing at these SP prices is unsettling for management. One possible way to get the financing needed for phase 2 and 3 is to partner with a big pharma. I'm sure TRIL is being scoped. Who will pull the trigger?
Bullboard Posts